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Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV), or human herpesvirus 8, is a lymphotropic virus strongly linked to
several AIDS-related neoplasms. The primary reservoir of infection consists of latently infected B lymphocytes and possibly
other mononuclear cells. Viral reactivation from latency and spread from this lymphoid reservoir is presumably required for
development of nonlymphoid tumors like KS. Here we show that deregulated expression of a single viral gene, ORF 50, which
encodes a transactivator able to selectively upregulate delayed-early viral genes, suffices to disrupt latency and induce the
lytic gene cascade in latently infected B cells. The identification of this gene opens the way to studies of the physiologic
mechanisms controlling reactvation of KSHV from latency. © 1998 Academic Press
Kaposi’s sarcoma (KS) is the most common neoplasm
in persons infected with the human immunodeficiency
virus (HIV), striking 15–25% of homosexual and bisexual
men with AIDS (Beral, 1991). Recently, a novel human
herpesvirus, Kaposi’s sarcoma-associated herpesvirus
(KSHV; also called human herpesvirus 8), has emerged
as a key factor in KS pathogenesis (9; see 10, 34, for
review). Infection by the virus is uncommon in the gen-
eral population, but strikingly more prevalent in groups at
high risk for KS (13, 16, 35). In HIV-positive subjects, prior
KSHV infection predicts a strongly increased risk of KS
tumorigenesis (24, 27); in the resulting tumors, the virus
can be found in a latent state in the majority of tumor
cells (37). Current evidence suggests that KSHV is nec-
essary for KS tumor development: in the absence of
KSHV infection, KS rarely if ever occurs. However, since
approximately 5% of the general population is KSHV-
seropositive (8) yet has a vanishingly small KS risk, other
cofactors—most notably HIV infection—are also re-
quired for tumorigenesis.
Based on nucleotide sequence analysis (33), KSHV
has been classified as a member of the lymphotropic (or
gamma) subfamily of the Herpesviridae, which also in-
cludes the transforming viruses Epstein–Barr virus (EBV)
and Herpesvirus saimiri (HVS). In keeping with this clas-
sification, virologic evidence supports the inference that
the primary target of viral infection is the B cell (1, 25, 40)
(though some other mononuclear cells may also be sus-
ceptible to infection (4). Also consistent with primary
lymphotropism is the fact that KSHV infection is also
tightly linked to two AIDS-related lymphoproliferative dis-
orders—primary effusion lymphoma (PEL) (6) and multi-
centric Castleman’s disease (36). But KS is an endothe-
lial, not a lymphoid, neoplasm, raising the issue of how
such endothelial cells are targeted during KS pathogen-
esis. Since latent KSHV infection is established well
before the onset of KS (24, 29), most authorities believe
that a necessary antecedent step in KS development is
reactivation of productive (lytic) KSHV infection from the
latently infected lymphoid reservoir. Efficient or sus-
tained reactivation—facilitated, for example, by HIV-in-
duced immunosuppression—would be expected to ele-
vate KSHV viral load, with resulting enhancement of the
opportunity for spread to extralymphoid targets like en-
dothelium. Consistent with this notion, clinical studies
have shown that KSHV nucleic acid is infrequently found
in peripheral blood lymphocytes (PBLs) of AIDS patients
before tumor development, but is detectable in at least
50% of patients following the onset of disease (1, 40), and
the viral load in circulating PBLs in those with AIDS or
AIDS-KS is higher than that seen in HIV-negative sub-
jects (3). Thus, active KSHV replication is strongly corre-
lated with increased risk of progression to KS.
Little is known about the switch from latency to lytic
reactivation in KSHV infection, but this subject has re-
ceived considerable attention in the distantly related EBV
(17, 26). As in most DNA viruses, expression of the lytic
cycle genes in EBV unfolds in a strict temporal sequence
and is governed by virus-encoded regulatory proteins.
The earliest class of such regulators is the so-called
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immediate-early (IE) class, which in EBV includes three
proteins known as Z (or BZLF1), R (or BRLF1), and M (or
BSMLF1). The Z and R proteins are known transcriptional
activators, while M appears to have complex pleiotropic
posttranscriptional effects. In classical experiments,
Miller and colleagues (12) demonstrated that ectopic
expression of the viral Z gene disrupts latency in B cells
and triggers the switch to the lytic gene cascade. Based
on these and other experiments, Z is now established as
the switch governing the latency-to-lytic transition in
EBV-infected B cells.
Examination of the KSHV genome sequence (33) re-
veals homologs of R and M, encoded by ORFs 50 and 57,
respectively. Here we report that the ORF 50 gene prod-
uct of KSHV, which is expressed very early in the lytic
cycle, can selectively activate the expression of down-
stream (delayed-early or DE) genes. More importantly,
forced expression of this gene, but not of a panel of other
candidate IE and DE genes, can trigger reactivation from
an established latent infection, establishing the KSHV R
protein as a critical regulator of the lytic cycle and an
important determinant of the natural history of KSHV
infection.
The studies presented here utilize a cell line called
BCBL-1, a B lymphocyte line derived from a PEL speci-
men and latently infected with KSHV (18, 31, 32). During
latency, viral gene expression is highly restricted, and
the cells do not produce virus (although 1 to 5% of the
cell population displays spontaneous reactivation). Upon
treatment with TPA or sodium butyrate, a lytic cascade of
viral gene expression is activated, resulting in viral
genomic replication, virion production, and cell lysis (31).
We have identified four candidate switch genes by
searching for the first genes to be expressed after cells
are stimulated by TPA. These include the genes ORF 50
(encoding the KSHV R protein), ORF 57 (M protein), K3,
and K5. The roles of R and M in EBV lytic induction have
been described above. K3 and K5 are homologs of each
other and distant homologs of BHV-4 immediate early
genes; they contain RING finger motifs known to partic-
ipate in protein–protein interactions. All of the messages
for these proteins appear within 6 h after stimulation of
viral reactivation in BCBL-1 cells by TPA (Lukac and
Ganem, manuscript in preparation; unpublished data of
R. Renne and J. Kirshner). Expression of these genes
precedes the activation of known DE genes, which are
defined as genes that are expressed prior to viral DNA
replication and whose expression is dependent upon
expression of viral IE genes. DE KSHV RNAs are typically
detected at 8–24 h postinduction and include such genes
as DNA polymerase (DNA pol) and the single-strand
DNA binding protein (DBP). Delayed early gene expres-
sion is followed by viral DNA replication, which is a
prerequisite for viral late gene expression. Therefore, the
very early kinetics of R, M, K3, and K5 expression sug-
gested that any or all of these proteins may play a role in
initiating the lytic program of gene expression required
for successful viral replication. Unfortunately, the toxicity
of cycloheximide in BCBL-1 cells has made it impossible
to rigorously establish that the transcripts of these genes
accumulate in the absence of de novo protein synthesis,
which is the formal definition of an immediate-early gene
product.
We focused initially on the ORF 50 (R) protein for two
reasons: (i) in EBV reactivation in B cells, the R gene is
coregulated with the switch gene (Z) and its product can
coordinately upregulate target DE genes when coex-
pressed with Z (17, 26), and (ii) the EBV R protein has
been suggested to serve as a molecular switch for EBV
reactivation in some nonlymphoid cells, e.g., certain cul-
tured epithelial cells (41).
Expression of KSHV ORF 50 (R). The genomic region
surrounding KSHV ORF 50 encodes multiple, abundantly
expressed messages, a detailed characterization of
which (by cDNA cloning, Northern blotting, primer exten-
sion, nuclease protection, 59 RACE, and RT–PCR) will be
presented elsewhere (Lukac and Ganem, manuscript in
preparation). Figure 1 presents a summary of the fea-
tures of ORF 50 expression pertinent to the present
study. ORF 50 message (Fig. 1A) is approximately 3.4
kilobases (kb) in length and is spliced: the 53-nucleotide
(nt) exon 1 is separated by a 959-nt intron from exon 2.
Exon 2 then extends through the remainder of ORF 50
and includes coding sequences from the downstream K8
and K8.1 genes. Although there are no additional splices
within ORF 50, the transcript undergoes three splices
within ORFs K8 and K8.1 and is polyadenylated at a
canonical poly(A) signal 39 to ORF K8.1. Although ORF 50
mRNA production commences within 6 h of TPA addition
to BCBL-1 cells, its levels continue to rise thereafter,
reaching a maximum at 48 h, when viral DNA replication
is also maximal.
The ORF 50 transcript is predicted to encode a 691-
amino-acid (aa) protein; inspection of its sequence re-
veals a number of domains that suggest it is a transcrip-
tion factor (Fig. 1B). ORF 50 encodes two putative nuclear
localization signals (NLSs), and indirect immunofluores-
cence of BCBL-1 cells induced to viral replication by TPA
reveals that R is indeed localized to the nucleus (Fig. 1C).
ORF 50 also encodes an amino-terminal basic domain
(with 19% basic residues) followed by a potential leucine
zipper (ZIP domain) and a carboxy-terminal domain con-
taining multiple acidic and bulky hydrophobic aas with
homology to the transcriptional activation domains (ADs)
of many mammalian, viral, and yeast transcription fac-
tors. Two independent regions of KSHV R share signifi-
cant homology to the R proteins encoded by the other
gammaherpesviruses (Fig. 1B). The N-terminal 238 aas
of KSHV R, including the basic domain, contain a region
20–32% identical and 41–52% similar to the R proteins of
EBV, HVS, bovine herpesvirus-4 (BHV-4), equine herpes-
virus (EHV), alcelaphine herpesvirus, and mouse herpes-
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virus-68 (MHV-68). In fact, this homologous region in the
EBV protein mediates dimerization and DNA binding of
EBV R (14). Likewise, 79 amino acids near the carboxy
terminus of KSHV R are 25–66% identical and 37–71%
similar to domains found in the cognate EBV, HVS,
BHV-4, and EHV proteins. This domain is included in a
region of EBV R which functions as an activation domain
when fused to the DNA binding domain of the yeast Gal4
protein (15). Thus, the two major functional domains of
the EBV R protein (DNA binding/dimerization and tran-
scriptional activation) are conserved with the KSHV R
protein, suggesting that the KSHV protein may function
similarly to its EBV counterpart in the viral life cycle.
KSHV R protein encodes a transactivator. In order to
express the R protein, we subcloned the 4.2-kb BspEI to
SalI fragment containing KSHV ORF 50 (see Fig. 1A) from
a KSHV genomic DNA library into the mammalian ex-
pression vector pcDNA3. The ORF 50 protein made from
this vector was expressed in the nuclei of transfected
CV-1 cells, confirming its proper subcellular localization
(not shown). To explore the potential of this protein to
regulate the expression of KSHV lytic cycle genes, we
examined its ability to transactivate a selection of KSHV
DE and late gene promoters in transient transfection
assays. These promoters included those for the DE
genes nut-1, thymidine kinase (TK), DBP, and DNA pol
and the late genes encoding assembly protein (AP) and
glycoprotein B (gB). We also examined its effects on the
promoter of the kaposin B gene, a latent gene whose
transcripts are also known to be further upregulated with
DE kinetics during the lytic cycle. For each of these
genes, we fused DNA fragments bearing 59 regulatory
sequences to the luciferase coding region of plasmid
pGL3 (see Materials and Methods). Each of these plas-
mids was cotransfected into CV-1 cells either with the
control pcDNA3 vector or with increasing amounts of
pcDNA3-ORF 50. Figure 2A shows a representative anal-
ysis of the nut-1 promoter. This promoter was activated
to over 40-fold at the lowest amount of ORF 50 plasmid
tested and reached a maximum of 45-fold when cotrans-
fected with 3 mg of pcDNA3 ORF 50.
Figure 2B summarizes our transfection data for all of
the tested promoters. Each was analyzed similarly to the
experiment shown in Fig. 2A; in Fig. 2B, we have de-
picted the maximal point on the titration curve for each
reporter. In these assays, the promoters of nut-1, TK,
kaposin, and DBP were all activated by ORF 50; nut-1
was activated to the highest value by ORF 50, although
TK activation reached 40-fold. Interestingly, nut-1 is
known to be the most highly expressed RNA in the virus
lytic cycle; in fact, this 45-fold induction of the nut-1
promoter exceeds the fold induction of steady-state lev-
els of endogenous nut-1 transcript after TPA-treatment of
BCBL-1 cells (38, 42). Of the delayed early promoters
tested, only the DNA pol promoter was not activated. The
inability of KSHV R to activate the DNA pol promoter
contrasts with the strong activation of the EBV DNA pol
promoter by EBV R (23). (We are currently dissecting the
promoter requirements for activation by KSHV ORF 50,
which may suggest explanations for this discrepancy.)
Further experiments revealed that ORF 50 did not acti-
vate the AP or gB promoters, both promoters of the late
class of RNAs (Fig. 2B). Thus, the ORF 50 (R) protein
activates delayed-early but not late KSHV promoters, a
pattern that is highly consistent with a proposed role for
this transactivator in regulating the cascade of lytic gene
induction. However, we note that results with transiently
expressed herpesviral reporter genes do not always re-
produce the patterns of regulation observed in the con-
text of viral replication in vivo.
FIG. 1. Expression of KSHV ORF 50 R protein. (A) The ORF 50
genomic locus. The top of the figure shows the ORFs located between
the indicated nucleotides in the KSHV genome. The large arrow indi-
cates the start site of transcription of ORF 50. The large bars below the
genomic locus designate the major transcript across ORF 50 as de-
tected by Northern blotting. (B) ORF 50 is homologous to EBV BRLF 1.
This diagram schematically depicts the putative structural and func-
tional domains of ORF 50. NLS, nuclear localization signal; LZ, leucine
zipper; ST, serine/threonine-rich; AD, activation domain. The bars un-
derneath the ORF delineate the boundaries of the two regions of
highest homology to the EBV R protein. (C) The ORF 50 R protein is
localized to the nucleus. These panels show results of immunofluores-
cence staining of BCBL-1 cells at 48 h after TPA addition, using sera
from rabbit before (left) or after (right) immunization with a recombinant
ORF 50 fragment (aa 484 to 691) expressed in E. coli. The reactivity with
anti-ORF 50 was detected using a FITC-conjugated goat anti-rabbit
antibody.
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KSHV R protein expression triggers reactivation from
latency. To determine whether the ORF 50 gene product
can indeed disrupt latency and trigger the KSHV lytic
cycle, we examined the effects of ectopic expression of
KSHV R protein (and of the other candidate activator
proteins) upon markers of viral replication in BCBL-1
cells. Several technical considerations are relevant to
analysis of this experiment. First, although BCBL-1 cells
are latently infected, even in the absence of TPA 1–3% of
BCBL-1 cells spontaneously enter the lytic cycle (this is
not unique to BCBL-1; other B cell lines bearing latent
KSHV (28) or EBV (17) genomes all display such sponta-
neous reactivation to various extents). This represents
the background level of reactivation against which de
novo induction must be measured. Second, for reasons
that are unclear, even the most potent chemical inducers
of lytic replication—e.g., TPA—result in detectable in-
duction in only 10–25% of BCBL-1 cells (again, this is also
true of all other latently infected B cell lines; many EBV
producer lines display only 5–10% infected cells post
phorbol treatment (17)). Third, the transfection of BCBL-1
cells is very inefficient, with optimal methods typically
delivering the exogenous DNA to only ;1% of exposed
cells. Therefore, even if the transfected switch gene were
highly effective as an inducer, the low frequency of de-
livery and the high spontaneous background of reactiva-
tion would make lytic induction difficult to observe in
mass culture, especially using biochemical methods
(e.g., Northern or immunoblotting) that do not examine
single cells. Accordingly, in our experiments, candidate
switch genes were transfected into BCBL-1 cells to-
gether with an expression vector for an irrelevant protein
(here, hepatitis delta antigen, HDAg) whose expression
was followed 48–84 h posttransfection by immunofluo-
rescence assay (IFA) to mark successfully transfected
cells. In each experiment, at least 1000 HDAg-positive
cells were scored by IFA for expression of two markers of
KSHV lytic reactivation: (i) ORF 59 protein, a DNA poly-
merase-associated processivity factor expressed as a
delayed-early gene (7, 22); and (ii) K8.1 protein, a viral
envelope glycoprotein expressed with late kinetics (30).
Each of these two markers was detected with monoclo-
nal antibodies specific for the corresponding protein.
Figure 3A shows the collated results of several such
experiments, in which BCBL-1 cells were transfected in
parallel with expression vectors for ORF 50 (R), ORF 57
(M), K3, or K5, the four candidate switch genes we had
earlier identified based on their patterns of expression
and homologies with known IE proteins of other herpes-
viruses. We also tested the impact of expression of the
K1 gene, a virally encoded membrane protein and potent
signal-transducing molecule that is also upregulated
during lytic infection (19, 20, 21). As a positive control,
BCBL-1 cells were transfected with the pcDNA3 and
HDAg vectors and induced with TPA; cells similarly
transfected but not treated with TPA served as controls
for spontaneous reactivation. Examination of the results
of the positive and negative control experiments was
instructive. Although in untransfected cultures, 1–3% of
cells were in the lytic cycle pre-TPA and 10–20% post-
TPA, in transfected cells the numbers were substantially
reduced, to 0.3–0.6 and 3–3.5% at 48 h posttransfection,
respectively, as judged by ORF 59 staining (Fig. 3A, left).
This most likely reflects the adverse impact of electro-
poration and transfection on cell physiology and is not
surprising when one considers that ca. 50% of treated
cells die following electroporation. By 60 h posttransfec-
tion (Fig. 3A, right), up to 6–7% of the transfected cells are
expressing ORF 59. This ca. 10-fold induction of replica-
FIG. 2. The KSHV ORF 50 R protein is a transcriptional transactivator.
(A) The R protein activates the nut-1 promoter. CV-1 cells were cotran-
fected with the indicated amounts of pcDNA3-ORF 50 and a constant
amount of pGL3-nut 1. Cells were harvested at 42 h posttransfection,
and luciferase activity was measured. Values are plotted as fold acti-
vation relative to the luciferase activity found in cells similarly cotrans-
fected with pGL3-nut 1 and the control pcDNA3 vector; values were
normalized to transfection efficiency, determined by cotransfection of a
B-galactosidase-expressing plasmid. Vertical bars represent standard
deviations of results from transfections performed in triplicate. (B) The
KSHV R protein transactivates viral delayed-early but not late promot-
ers. Transfections were performed with varying amounts of pcDNA3-
ORF 50 and fixed amount of luciferase reporter constructs driven by the
indicated promoters, as in A; the maximum amount of transactivation
observed in each dose–response experiment is plotted here. Error bars
are as in A. See text for construction of all reporter plasmids.
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tion by TPA is highly reproducible and is similar in mag-
nitude to the induction ratio produced by TPA in cultures
not exposed to electroporation. In addition, we note that
staining for the DE ORF 59 protein was consistently
2-fold more sensitive that staining for the late K8.1 anti-
gen. This might be due to the different affinities of the two
mAbs used for detection or could reflect possible abor-
tive lytic induction in some cells, in which DE genes are
triggered without progression to DNA synthesis and late
gene expression.
Figure 3A (left) shows that, of the tested genes, only
expression of ORF 50 led to induction of detectable lytic
cycle markers: the M, K1, K3, and K5 expression vectors
had no impact on lytic reactivation. Importantly, when
examined quantitatively, the induction of replication by
KSHV R protein in transfected cells was comparable in
efficiency to that induced by TPA treatment (see also Fig.
3A, right). Although for the reasons outlined above, anal-
ysis of DNA replication in bulk cultures was not possible
here, strong indirect evidence points to the induction by
KSHV R protein of viral DNA replication as well as gene
expression. Figure 3B shows that when ORF 50 trans-
fection was performed in the presence of the viral DNA
polymerase inhibitor foscarnet (phosphonoformate, PFA),
DE (ORF 59) gene upregulation was unaffected but late
(K8.1) gene expression was profoundly inhibited. Since
late gene (but not DE) expression is dependent on DNA
replication, this experiment provides strong evidence
that authentic genomic replication was ongoing in trans-
fected cells. Taken together, the evidence strongly indi-
cates that the full program of KSHV reactivation was
induced by ectopic R expression. Importantly, a genomic
construct carrying R coding seqeunces and 59 regulatory
elements but no exogenous promoter to drive deregu-
FIG. 3. KSHV R protein expression induces the KSHV lytic cascade in BCBL-1 cells. (A) (Left) The KSHV ORF 50 R protein induces the lytic antigens
ORF 59 and K8.1 as efficiently as TPA. Cells were electroporated with vectors expressing the indicated proteins and hepatitis delta antigen (HDAg).
Successfully transfected cells, identified by positive staining for HDAg, were scored 48 h posttransfection for expression of either ORF 59 or K8.1; 1000
to 2500 transfected cells were counted for each electroporation; the percentage of transfected cells expressing the respective KSHV lytic marker is
indicated above each bar. The bars indicate the fold induction of the lytic markers relative to cells electroporated in the absence of TPA with the
control pcDNA3 vector. Note: in columns ORF 50 no CMV, cells were transfected with a clone bearing ORF 50 coding and promoter sequences in
the absence of an exogenous CMV promoter/enhancer. (Right) Induction of KSHV lytic genes by deregulated ORF 50 expression in transfected BCBL-1
cells. Experiment performed exactly as in A (left), except that staining was carried out at 60 h posttransfection. (B) Late but not DE gene expression
is blocked by phosphonoformate (PFA). BCBL-1 cells were transfected with the indicated plasmid plus an HDAg expression vector and then incubated
in either the absence or the presence of TPA; one parallel culture was exposed to both TPA and PFA, as indicated. At 60 h posttransfection,
HDAg-positive cells were scored for expression of ORF 59 (dark bars) or K8.1 (light bars). Number atop each bar denote the percent of scored cells
positive for each marker; height of bars denotes fold induction over that induced by transfection of pcDNA3 control vector in the absence of TPA.
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lated expression (Fig. 3A, left, labeled “ORF 50 no CMV”)
did not induce lytic reactivation. This is consistent with
the notion that some cellular stimulus (e.g., TPA-induced
activation of host transcription factors controlling the
ORF 50 promoter) is required for the physiologic induc-
tion from latency. Finally, additional evidence for lytic
induction comes from analysis of the cytopathic effect of
lytic induction by R protein expression. As shown in Fig.
4, R-transfected cells in which ORF 59 or K8.1 expression
was induced frequently showed bi- or multinucleate syn-
cytium formation, a characteristic cytopathic effect in
many herpesvirus infections.
Our results—and similar recent findings of Sun and
colleagues (39)—are formally analogous to those that
established the EBV Z gene as the molecular switch
governing lytic reactivation in that virus (12) and point
strongly to a similar role for the R protein in KSHV
reactivation. If so, then study of the regulation of the R
promoter by cellular factors may allow definition of the
host machinery that governs reactivation and thereby
influences subsequent pathogenetic events in infected
patients.
Plasmids. All plasmids were propagated in Esche-
richia coli DH5a and were purified by alkaline lysis and
double banding in cesium chloride. All genomic se-
quence positions are according to Russo et al. (33). The
source of starting genomic DNA for all clones was our
KSHV genomic lambda library (42). Plasmids used for
expression of KSHV proteins and their construction are
as follows: pcDNA3-ORF 50 was constructed by subclon-
ing the 7-kb SalI fragment spanning nt 67861 to 74810
into SalI-digested pBluescript II (KS1), generating the
FIG. 4. Induction by KSHV R protein expression of bi- and multinucleate cells expressing lytic cycle markers. Cells transfected with expression
vectors for HDAg and ORF 50 were examined at 48 h posttransfection by staining for HDAg (green) and either ORF 59 (orange, left panels) or K8.1
(orange, right panels). (Top left) Typical single cell staining for both HDAg and ORF 59; (bottom left) ORF 59-positive syncytium containing 3–4
HDAg-positive nuclei; (top and bottom right) two different binucleate cells expressing nuclear HDAg and cytoplasmic/membrane K8.1 (see text for
details of staining).
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plasmid pBS KS-Sal 7. The ORF 50 genomic expression
vector was then constructed in two steps. Exon 2, con-
taining the body of ORF 50, was first subcloned using the
unique SpeI site at nt 72223 and the 39 SpeI site contrib-
uted by the pBluescript polylinker. This fragment was
cloned into pcDNA3 which had been linearized with
XbaI, generating the plasmid pcDNA3-ORF 50 short. The
entire ORF 50 locus was then reconstructed by digesting
and blunting pBS-Sal 7 at the BspE1 site at nt position
71251 and then removing the 1316-nt fragment using
Bsu36I. This was cloned into pcDNA3-ORF 50 short,
which had been digested with EcoRV and Bsu36 I, to
create pcDNA3-ORF 50.
pBS-ORF 50 was constructed by digesting pBS-Sal 7
with NsiI at genomic position 70703 and then blunting
with Klenow polymerase. The KSHV sequences up-
stream of that site were then removed by cutting with
XhoI in the polylinker, blunting with T4 DNA polymerase,
and then religating the plasmid. The bovine growth hor-
mone poly(A) addition sequence was then removed from
pcDNA3 by digesting it with EcoRI/PvuII. This fragment
was ligated into the ORF 50 construct that had been
digested with XbaI, blunted with Klenow, and then di-
gested with EcoRI.
pRSET 0.8 was generated by subcloning the SmaI/
SacI fragment from the 39 terminus of ORF 50 into pRSET
B (Invitrogen) that had been digested with PvuII/SacI.
pcDNA3.1-ORF 57-Hygro was constructed by subclon-
ing the 1496-nt ApaLI to Bst98I fragment, after Klenow
blunting, into pcDNA 3.1 that was linearized with EcoRV.
The construction of pcDNA- ORF K1 is described in
Lagunoff et al. (20).
pcDNA3-K3 and pcDNA3-K5 were constructed by PCR
amplification of the respective ORFs using primers that
introduced 59 BamHI and a 39 EcoRI restriction sites.
These PCR products were digested with those enzymes
and cloned into the corresponding sites in pcDNA3.
Numerous reporter plasmids were constructed using
the luciferase reporter plasmid pGL3-Basic (Promega). In
most cases, we attempted to use the native initiating
AUG for each KSHV gene to control translation of lucif-
erase. The reporters and construction are as follows:
pGL3-TK was constructed by PCR amplification of a
1456-nt fragment from genomic positions 33927 to
35383, using a primer that introduced an NcoI site at the
initiation codon of TK. Digestion of this fragment with
NcoI and HindIII yielded two fragments: one ended with
only NcoI sites and the other ended with NcoI and HindIII
sites. The NcoI/HindIII fragment was first cloned into
pGL3-Basic that had been digested with both enzymes,
to yield pGL3-TK N/H. This was followed by insertion of
the NcoI fragment at the NcoI site in this plasmid.
pGL3-gB was constructed by PCR amplification of a
1216-nt fragment from genomic positions 7483 to 8699.
One primer introduced an NcoI site at the initiation
codon of gB. The PCR product was digested with NcoI
and HindIII and subcloned into NcoI/HindIII-digested
pGL3-Basic.
pGL3-pol was constructed by PCR amplification of the
1569-nt fragment from genomic position 9794 to 11363.
One primer introduced an NcoI site at the initiation
codon of DNA pol. This product was digested with EcoRV
and NcoI and cloned into pGL3-Basic which had been
digested with SmaI and NcoI.
pGL3-DBP was constructed by subcloning the 1326-nt
BamHI/KpnI fragment from genomic positions 1883 to
3209 into pBluescript (SK1) to generate pBS-DBP. The
promoter was then liberated from this plasmid using SacI
and NcoI donated by the pBS polylinker and cloned into
pGL3-Basic that had been digested with the same en-
zymes.
pGL3-nut1 was constructed by cloning the 1737-nt
BglII/NcoI fragment from genomic positions 27199 to
28936 into pGL3-Basic that had been digested with the
same enzymes.
pGL3-B3 contains the kaposin promoter and was con-
structed by cloning the 1434-nt XhoII/KpnI fragment from
genomic positions 120163 to 118729 into pGL3-Basic that
had been digested with BglII and KpnI.
pGL3-AP was constructed by cloning the 696-nt SacI/
EcoRV fragment from genomic positions 32362 to 31666
into pGL3-Basic that had been digested with SmaI. The
SalI site was blunted with Klenow polymerase. The initi-
ating ATG of the AP ORF (nt position 31687) was then
changed to TTG using PCR mutagenesis.
pnut24 expresses histidine-tagged HDV LDAg from
pcDNA3.
PcDNA 3.1-lac Z expresses B-galactosidase and was
used as an internal control for all transfections.
Cell lines and transfections. The cell line BCBL-1 was
propagated and maintained as in Renne et al. (32). For
electroporation, cells were split to a density of 4 3
105/mL 18–24 h prior to electroporating. On the day of
electroporation, cells were washed twice in 13 PBS and
then resuspended in minimal RPMI 1640 media (supple-
mented with 10 mM dextrose in Tris-buffered saline/0.1
mM dithiothreitol) at a density of 1 3 107 cells/mL. Cells
were aliquotted in 0.3-mL volumes to electroporation
cuvettes (0.42 cm), and DNA was added to the cells. For
induction experiments, 3 mg of each respective KSHV
expression vector and 2 mg of pnut24 were electropo-
rated with 960 mF, 150 mV. Electroporated cells were
then transferred to fresh growth media or media contain-
ing 20 ng/mL TPA and/or 0.5 mM PFA. Cells were har-
vested at 48 to 84 h postelectroporation and analyzed by
IFA.
CV-1 cells were propagated and maintained in DME-
H21 media supplemented with 10% fetal calf serum and
pennicillin/streptomycin. For transfections, low-passage
cells were plated at 3 3 105 cells per 60-mm tissue
culture dish and grown overnight. On the day of trans-
fection, monolayers were fed 3 h before DNA addition.
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DNA amounts used were as listed in the appropriate
figures; pcDNA3 was used to normalize total DNA
amounts for each transfection. DNA was precipitated
using the calcium phosphate procedure with the N,N-
bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES)
modification (11). The precipitate was left on the cells for
6 h, then the cells were shocked with 15% glycerol (in
BES-buffered saline) for 1 min, and fresh medium added.
Cells were harvested at 42 to 48 h post glycerol shock for
luciferase and b-galactosidase assays. Data shown in
Fig. 3 are the result of at least two experiments per-
formed in triplicate for each reporter.
Luciferase and b-galactosidase assays. Cells were
washed twice in 3 mL 13 PBS at room temperature and
then incubated for 30 min with rocking with 0.2 mL
reporter lysis buffer (Promega). Cells were scraped and
collected, and then debris was removed by centrifuga-
tion for 1 min at 16,000 rpm in a microcentrifuge. Super-
natants were transferred to new tubes, and 20- and
50-mL aliquots were analyzed by luciferase or b-galac-
tosidase assays, respectively, according to the manufac-
turer’s instructions (Promega).
Antibodies and IFA. Antibody 733 vs HDAg was as
described in Brazas and Ganem (5). Rabbit antiserum
D3861 (Animal Pharm Services) was generated vs the
His-tagged protein expressed from pRSET-ORF 50. For
IFA, cells were washed twice in 13 PBS, and then
2.5 3 105 cells were applied in 0.2-mL volumes to
individual wells of a six-well cell staining slide (Cel-
Line Associates). Cells were allowed to adhere for 30
min, after which the remaining liquid was removed by
suction. Slides were immediately fixed in 50% metha-
nol/50% acetone, which had been precooled to
220°C. The slides were kept covered at 220°C for 10
min and then removed and air dried under a tissue
culture hood for 5 min. Slides were then stored at
270°C or analyzed immediately. For immunofluores-
cence staining, cells were rehydrated in 0.2 mL of 3%
bovine serum albumin (BSA) for 15 min. This was
removed by suction, and cells were blocked in 3%
BSA/1% glycine (blocking buffer) for 30 min. This was
removed, and cells were incubated with the anti-DAg,
at a dilution of 1:300, and either of the KSHV mono-
clonal antibodies (1H10 vs ORF 59 and 19B4 vs K8.1;
kindly provided by B. Forghani) at a dilution of 1:1000.
Antibodies were diluted in blocking buffer, and incu-
bation was for 1 h. This was followed by two 30-min
washes in 13 PBS/4% Tween 20, and one 30-min wash
in 13 PBS. Excess PBS was aspirated, and the cells
were subjected to the secondary stain. This step uti-
lized FITC-conjugated goat anti-rabbit whole antibody
and TRITC-conjugated goat anti-mouse F(ab)2 frag-
ments, both diluted 1:300. Secondary reagents were
incubated with the cells for 1 h and then washed as
above.
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